Search research articles
Contact Us
Filters
Showing results (531-540 of 598) with videos related to
Page
of 60
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A Korde, Mark R Somerfield, Lisa A Carey, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
Marjorie C Green, Aman U Buzdar, Terry Smith, et al.
Cancer
|
June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
W Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 16, 2026
Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial
Simona F Shaitelman, Savitri Krishnamurthy, Heather Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
JAMA Oncology
|
February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Otto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Neuron
|
June 30, 2001
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice
R A Cherny, C S Atwood, M E Xilinas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 19, 2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.
Page
of 60
Search research articles
Search
Showing results (531-540 of 598) with videos related to
Sort By:
Page
of 60
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A Korde, Mark R Somerfield, Lisa A Carey, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
Marjorie C Green, Aman U Buzdar, Terry Smith, et al.
Cancer
|
June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
W Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 16, 2026
Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial
Simona F Shaitelman, Savitri Krishnamurthy, Heather Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
JAMA Oncology
|
February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Otto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Neuron
|
June 30, 2001
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice
R A Cherny, C S Atwood, M E Xilinas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 19, 2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.
Page
of 60